vision: safety analysis of 177lu-psma-617 in mcrpc
Published 6 months ago • 34 plays • Length 1:35Download video MP4
Download video MP3
Similar videos
-
3:03
vision: tolerability of 177lu-psma-617 by treatment exposure in patients with mcrpc
-
3:56
vision: 177lu-psma-617 in psma-positive mcrpc
-
1:28
vision: 177lu-psma-617 in psma-positive mcrpc
-
4:48
vision: lu-177-psma-617 in mcrpc
-
0:57
real-world outcomes of 177lu-psma-617 in mcrpc
-
3:17
safety and efficacy of 177lu-psma-617
-
6:45
177lu-psma-617 for prostate cancer: therap, vision, upfrontpsma and lutectomy
-
11:01
lutetium-177: psma guided treatment | #prostatecancer | #markscholzmd | #pcri
-
15:35
lu-psma radioligand therapy
-
3:36
the palliative benefits of lutetium-177-psma
-
5:30
fractionated dose 177lu-psma-617 in patients with mcrpc
-
5:45
efficacy and toxicity of 177lu-psma-617 for mcrpc in a real-world setting
-
1:00
is there are role for 177lu-psma-617 in earlier lines of treatment for mcrpc?
-
0:29
a phase i/ii dose-escalation study of fractionated dose 177lu-psma-617 for progressive mcrpc
-
2:37
therap: cabazitaxel versus 177lu-psma-617 for mcrpc
-
1:08
psma imaging pre- and post-177lu-psma-617 treatment in mcrpc
-
11:07
phase 3 vision study of 177lupsma 617 for metastatic castration-resistant prostate cancer
-
![psmafore results: [177lu]lu-psma-617 in taxane-naive patients with mcrpc](https://i.ytimg.com/vi/upLVFTNeq9o/mqdefault.jpg)
10:20
psmafore results: [177lu]lu-psma-617 in taxane-naive patients with mcrpc
-
5:27
177lu-psma-617 radionuclide therapy in mcrpc
-
1:38
dr. sartor on outcomes with 177lu-psma-617 after radium-223 in mcrpc
-
7:14
vision study
-
5:37
177lu-psma-617 for the early treatment of prostate cancer